Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • Seed Grant News
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Where to Begin
    • Caregivers & Families
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Resources →
      • NCCN Guidelines for Patients
      • Patient Support Tools
      • Create Your Health Care Team
      • Patient Health Diaries
      • Support Groups
      • Financial Aid
  • HOW YOU CAN HELP
    • Planned Giving
    • Donor-Advised Funds
    • Event Calendar
    • Get Inspired
    • Fundraising Resources
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • More Ways to Give →
      • You Can Help Funds
      • Host Your Own Event
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Jason Link, Ph.D.

Jason Link, Ph.D.

Jason Link, Ph.D.
Jason Link, Ph.D.
Associate Adjunct Professor
Department of Surgery, Surgical Oncology

University of California, Los Angeles (UCLA)
Los Angeles, CA

The Nature of Effective Tertiary Lymph Structures from Long-Term Surviving Patients with Metastatic PDAC, and the Mechanisms by Which Most PDAC Tumors Circumvent Them

Overview

Aim: Therapy

Pancreatic Adenocarcinoma carries a dismal prognosis for almost all patients; however, a small fraction of patients are able to survive for many years despite the presence of metastatic PDAC. In order to suppress metastatic PDAC, the immune system in these patients constantly generates new T cells that attack the ever-changing tumor. This anti-tumor immune response takes place within the tumor in regions called tertiary lymph structures (TLSs). However, not all TLSs are created equal and the properties that make TLSs so effective in long-term surviving patients are unknown. This proposal is designed to identify how these TLSs can successfully control metastatic PDAC. In stark contrast to these long-term survivors are the majority of PDAC patients with aggressive disease that metastasizes to the liver. Tumors in these patients undergo constant stress that should alert the immune system to generate TLSs to attack them. However, disconnects in that alert system allow aggressive tumors to thrive. The second half of this proposal is designed to identify how aggressive tumors prevent TLSs from forming, and to identify therapeutics that re-establish TLS formation in aggressive PDAC tumors. Deciphering the mechanisms by which PDAC tumors either support or circumvent effective TLSs will be critical in order to therapeutically ignite effective immune responses that can naturally control this devastating disease.

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Financial Information
  • Contact